Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy
Status:
Terminated
Trial end date:
2016-05-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess analgesic efficacy of ASP3662 relative to placebo in
subjects with painful diabetic peripheral neuropathy (PDPN) as well as assess the safety and
tolerability of ASP3662 relative to placebo.
The analgesic effect is evaluated by measuring percent responders, change in daily worst pain
score, change in average daily pain score, Patient Global Impression of Change (PGIC) and
Clinical Global Impression of Change (CGIC).